Witjes VM - Search Results

1

Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.

Witjes VM, de Hullu JA, Hermkens DMA, Smolders YHCM, Swillens JEM, Slob SL, Bosse T, Mourits MJE, Ausems MGEM; Tumor‐First Implementation Group; Ligtenberg MJL, Hoogerbrugge N. Witjes VM, et al. Int J Cancer. 2025 Aug 1;157(3):504-512. doi: 10.1002/ijc.35440. Epub 2025 Apr 16. Int J Cancer. 2025. PMID: 40240123 Free PMC article.

2

Non-serous ovarian cancer in PTEN Hamartoma Tumor Syndrome: additional evidence for increased risk.

Schei-Andersen AJ, Witjes VM, Vos JR, Mensenkamp AR, van Altena A, Schieving J, Simons M, Schuurs-Hoeijmakers JHM; PTEN Study Group; Hoogerbrugge N. Schei-Andersen AJ, et al. Among authors: witjes vm. Fam Cancer. 2025 Mar 18;24(2):28. doi: 10.1007/s10689-025-00453-z. Fam Cancer. 2025. PMID: 40100464 Free PMC article.

3

Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow.

Witjes VM, Hermkens DMA, Swillens JEM, Smolders YHCM, Mourits MJE, Ausems MGEM, de Hullu JA, Ligtenberg MJL, Hoogerbrugge N. Witjes VM, et al. Fam Cancer. 2024 Nov;23(4):429-436. doi: 10.1007/s10689-024-00398-9. Epub 2024 May 29. Fam Cancer. 2024. PMID: 38811422 Free PMC article. Review.

4

The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?

Witjes VM, Ligtenberg MJL, Vos JR, Braspenning JCC, Ausems MGEM, Mourits MJE, de Hullu JA, Adang EMM, Hoogerbrugge N. Witjes VM, et al. Gynecol Oncol. 2023 Jul;174:121-128. doi: 10.1016/j.ygyno.2023.04.029. Epub 2023 May 12. Gynecol Oncol. 2023. PMID: 37182432 Free article.

5

[Genetic testing in epithelial ovarian cancer: implementation of the 'Tumor-First' workflow].

Witjes VM, Hoogerbrugge N. Witjes VM, et al. Ned Tijdschr Geneeskd. 2023 Mar 16;167:D7006. Ned Tijdschr Geneeskd. 2023. PMID: 36928393 Dutch.

6

Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.

Witjes VM, Braspenning JCC, Hoogerbrugge N, Smolders YHCM, Hermkens DMA, Mourits MJE, Ligtenberg MJL, Ausems MGEM, de Hullu JA. Witjes VM, et al. Fam Cancer. 2023 Jan;22(1):1-11. doi: 10.1007/s10689-022-00294-0. Epub 2022 May 16. Fam Cancer. 2023. PMID: 35570228 Free PMC article.

7

Universal genetic assessment for women with ovarian cancer not yet achieved: The promises of universal tumor DNA testing.

Witjes VM, Vos JR, Ligtenberg MJL, Hoogerbrugge N. Witjes VM, et al. Gynecol Oncol Rep. 2021 Jun 30;38:100825. doi: 10.1016/j.gore.2021.100825. eCollection 2021 Nov. Gynecol Oncol Rep. 2021. PMID: 34977313 Free PMC article. No abstract available.

8

Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.

Witjes VM, van Bommel MHD, Ligtenberg MJL, Vos JR, Mourits MJE, Ausems MGEM, de Hullu JA, Bosse T, Hoogerbrugge N. Witjes VM, et al. Gynecol Oncol. 2022 Jan;164(1):221-230. doi: 10.1016/j.ygyno.2021.10.072. Epub 2021 Oct 23. Gynecol Oncol. 2022. PMID: 34702566 Free article.

9

Reducing versus Embracing Variation as Strategies for Reproducibility: The Microbiome of Laboratory Mice.

Witjes VM, Boleij A, Halffman W. Witjes VM, et al. Animals (Basel). 2020 Dec 17;10(12):2415. doi: 10.3390/ani10122415. Animals (Basel). 2020. PMID: 33348632 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters